Skip to content
HER3-DXd & Motixafortide episode artwork

Sep 14, 2023 11 min

HER3-DXd & Motixafortide

from OncoPharm Hosted by John Bossaer

An experimental drug for EGFRm NSCLC, patritumab deruxtecan (HER3-DXd), raises some eyebrows and a new agent is FDA-approved for hematopoietic stem cell mobilization (motixafortide).

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

HER3-DXd & Motixafortide

0:00 11:16

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 11 minutes long.

When was this OncoPharm episode published?

This episode was published on September 14, 2023.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.